Akanda Corp. (NasdaqCM: AKAN)
Health Care · Pharmaceuticals · CA
$3.73
-3.37% today · -95.6% 1Y
Akanda Corp. (NasdaqCM: AKAN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.03M and employs 8 people.
Over the last twelve months the share price has lost 95.6%, trading between 2.30 and 209.03.
Tweenvest scores Akanda Corp. across four factors: quality 10/100, value 52/100, growth 100/100. Its strongest factor is growth.
AKAN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.03M
- Revenue (TTM)
- $258.07K
- P/E
- —
- EPS
- -662.22
- Dividend yield
- —
- Beta (5Y)
- 14.22
- 52-week high
- $209.03
- 52-week low
- $2.30
- Avg volume (3M)
- —
- Shares outstanding
- 785.65K
- Employees
- 8
- Next earnings
- —
About Akanda Corp.
Akanda Corp., operating through its various subsidiary entities, focuses on the cultivation, production, and distribution of cannabis products. The company's operations span the United Kingdom, Lesotho, and other global regions, with a specific aim to provide cannabis-derived items for medical and wellness purposes. Formed in 2021, Akanda Corp. is based out of its main office in New Romney, United Kingdom.
- ISIN
- CA00971M7008
- Listed since
- Mar 15, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.82 | +0.07% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.26 | +0.08% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.29 | +3.74% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.41 | +1.56% |
Figures last refreshed Aug 18, 2026.